Ana Ramirez Berlioz, MD
Endocrinology, Diabetes & Metabolism · Pueblo, CONPI 1386025229
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,393 of the $3,792 with a category attached, or 63.1%. 19 manufacturers reported payments, led by Medtronic at 43.3% of the total. Reporting peaked in 2019 at $1,545 and has fallen 79.9% since, to $310 in 2025.
Across 117 payments — averaging $32.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Tandem Diabetes Care, Inc.$511
- Lilly USA, LLC$448
- Novo Nordisk$407
- Boehringer Ingelheim$170
- Sanofi-aventis U.S. LLC$85
- plus $527 from 13 others
What the payments were for
- Travel & lodging$1,34035%
- Food & beverage$2,39363%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 16 | $1,644 |
| Tandem Diabetes Care, Inc. | 7 | $511 |
| Lilly USA, LLC | 21 | $448 |
| Novo Nordisk | 32 | $407 |
| Boehringer Ingelheim | 8 | $170 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| AbbVie | 5 | $81 |
| Mannkind Corporation | 2 | $75 |
| Radius Health, Inc. | 3 | $55 |
| Dexcom, Inc. | 3 | $53 |
| Bayer | 3 | $46 |
| Alvogen Inc | 2 | $44 |
| Amgen | 3 | $42 |
| BETA Bionics, Inc. | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Sequel Med Tech, LLC | 1 | $22 |
| IBSA Pharma Inc. | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,792 in reported general payments places this provider in the 70th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 184 | $305,057 |
| TrulicityDulaglutide | 130 | $202,183 |
| ForteoTeriparatide | 45 | $196,298 |
| MounjaroTirzepatide | 114 | $180,405 |
| JardianceEmpagliflozin | 112 | $164,280 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $73,156 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $66,726 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 24 | $59,631 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $50,225 |
| RybelsusSemaglutide | 17 | $41,012 |
| Humalog Kwikpen U-100Insulin Lispro | 88 | $37,301 |
| Novolog FlexpenInsulin Aspart | 96 | $34,705 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $23,730 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $15,322 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $15,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Forteo, Mounjaro, Humalog, Insulin Lispro | $448 | $587,774323 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $407 | $352,040219 claims |
| Boehringer IngelheimJardiance | $170 | $164,280112 claims |
| Sanofi-aventis U.S. LLCLantus | $85 | $4,02928 claims |
| AbbVieSynthroid | $81 | $1,80718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Pueblo
- Anh-Thu NguyenPueblo$1K
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
- Irinel StanciuArvada$104K
- Robert EckelAurora$66K
- Marc Andre CornierAurora$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.